Monthly jab could provide ‘life-changing’ treatment for severe asthma
How the severity of asthma is diagnosed
A new monthly injection, Tezepelumab, could enable severe asthma patients to stop taking daily steroid tablets without affecting their symptoms.
The Wayfinder trial, led by King's College London, involved almost 300 people with severe, uncontrolled asthma who were on daily steroid medication.
The trial found that 90 per cent of patients treated with Tezepelumab were able to reduce their daily steroid dose.
Over half of the patients receiving the injection were able to stop daily steroids completely after 12 months, while two-thirds stopped having asthma attacks.
Experts believe this development could transform the lives of people with severe asthma, offering an alternative to steroids, which have significant long-term side effects.